S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20

AnaptysBio Stock Forecast, Price & News

-0.68 (-2.14%)
(As of 11/26/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
119,709 shs
Average Volume
302,749 shs
Market Capitalization
$856.05 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive ANAB News and Ratings via Email

Sign-up to receive the latest news and ratings for AnaptysBio and its competitors with MarketBeat's FREE daily newsletter.

AnaptysBio logo

About AnaptysBio

AnaptysBio, Inc. is a clinical stage biotechnology company, which engages in the development of antibody product candidates. Its products pipeline include ANB030, ANB030, and Imsidolimab. It also offers SHM platform that replicate the natural process of somatic hypermutation embedded within the human immune system to rapidly develop a diverse range of therapeutic-grade antibodies in vitro. The company was founded by Andrew B. Cubitt, William J. Boyle, Kevin J. Kinsella, and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.


Analysts Expect AnaptysBio, Inc. (NASDAQ:ANAB) to Announce $0.65 EPS
November 17, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$75 million
Book Value
$13.94 per share


Net Income
$-19.93 million
Pretax Margin




Free Float
Market Cap
$856.05 million

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

1.87 out of 5 stars

Medical Sector

748th out of 1,391 stocks

Pharmaceutical Preparations Industry

357th out of 669 stocks

Analyst Opinion: 2.2Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -

AnaptysBio (NASDAQ:ANAB) Frequently Asked Questions

Is AnaptysBio a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AnaptysBio in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" AnaptysBio stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ANAB, but not buy additional shares or sell existing shares.
View analyst ratings for AnaptysBio
or view top-rated stocks.

How has AnaptysBio's stock been impacted by Coronavirus?

AnaptysBio's stock was trading at $15.23 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ANAB stock has increased by 104.3% and is now trading at $31.12.
View which stocks have been most impacted by COVID-19

When is AnaptysBio's next earnings date?

AnaptysBio is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for AnaptysBio

How were AnaptysBio's earnings last quarter?

AnaptysBio, Inc. (NASDAQ:ANAB) issued its quarterly earnings results on Thursday, November, 4th. The biotechnology company reported ($0.24) EPS for the quarter, beating the Zacks' consensus estimate of ($0.85) by $0.61. AnaptysBio had a trailing twelve-month return on equity of 2.17% and a net margin of 6.87%.
View AnaptysBio's earnings history

What price target have analysts set for ANAB?

6 Wall Street analysts have issued twelve-month price targets for AnaptysBio's shares. Their forecasts range from $29.00 to $44.00. On average, they expect AnaptysBio's share price to reach $35.50 in the next year. This suggests a possible upside of 14.1% from the stock's current price.
View analysts' price targets for AnaptysBio
or view top-rated stocks among Wall Street analysts.

Who are AnaptysBio's key executives?

AnaptysBio's management team includes the following people:
  • Hamza Suria, President, Chief Executive Officer & Director
  • Eric J. Loumeau, Chief Operating Officer & General Counsel (LinkedIn Profile)
  • Dennis M. Mulroy, Chief Financial Officer
  • Paul F. Lizzul, Chief Medical Officer
  • David McKeon, Vice President & Controller

What other stocks do shareholders of AnaptysBio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AnaptysBio investors own include bluebird bio (BLUE), ImmunoGen (IMGN), NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Amarin (AMRN), Editas Medicine (EDIT), Illumina (ILMN), Clovis Oncology (CLVS), Twilio (TWLO) and AbbVie (ABBV).

When did AnaptysBio IPO?

(ANAB) raised $60 million in an IPO on Thursday, January 26th 2017. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Credit Suisse and Stifel served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

What is AnaptysBio's stock symbol?

AnaptysBio trades on the NASDAQ under the ticker symbol "ANAB."

Who are AnaptysBio's major shareholders?

AnaptysBio's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.82%), Dimensional Fund Advisors LP (2.75%), Great Point Partners LLC (2.00%), Rock Springs Capital Management LP (1.95%), Geode Capital Management LLC (1.30%) and Goldman Sachs Group Inc. (1.26%). Company insiders that own AnaptysBio stock include Ecor1 Capital, Llc, Eric J Loumeau and Hamza Suria.
View institutional ownership trends for AnaptysBio

Which major investors are selling AnaptysBio stock?

ANAB stock was sold by a variety of institutional investors in the last quarter, including BVF Inc. IL, Renaissance Technologies LLC, Two Sigma Advisers LP, Morgan Stanley, Two Sigma Investments LP, Citigroup Inc., Geode Capital Management LLC, and Rafferty Asset Management LLC. Company insiders that have sold AnaptysBio company stock in the last year include Eric J Loumeau, and Hamza Suria.
View insider buying and selling activity for AnaptysBio
or view top insider-selling stocks.

Which major investors are buying AnaptysBio stock?

ANAB stock was acquired by a variety of institutional investors in the last quarter, including Great Point Partners LLC, Eversept Partners LP, Goldman Sachs Group Inc., Fisher Asset Management LLC, Ensign Peak Advisors Inc, Ziegler Capital Management LLC, Panagora Asset Management Inc., and Millennium Management LLC.
View insider buying and selling activity for AnaptysBio
or or view top insider-buying stocks.

How do I buy shares of AnaptysBio?

Shares of ANAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AnaptysBio's stock price today?

One share of ANAB stock can currently be purchased for approximately $31.12.

How much money does AnaptysBio make?

AnaptysBio has a market capitalization of $856.05 million and generates $75 million in revenue each year. The biotechnology company earns $-19.93 million in net income (profit) each year or $0.28 on an earnings per share basis.

How many employees does AnaptysBio have?

AnaptysBio employs 94 workers across the globe.

What is AnaptysBio's official website?

The official website for AnaptysBio is www.anaptysbio.com.

Where are AnaptysBio's headquarters?

How can I contact AnaptysBio?

AnaptysBio's mailing address is 10421 PACIFIC CENTER COURT SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at (858) 362-6295 or via email at [email protected].

This page was last updated on 11/28/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.